US 11,884,978 B2
Pathogen biomarkers and uses therefor
Richard Bruce Brandon, Boonah (AU); Brian Andrew Fox, Seattle, WA (US); Leo Charles McHugh, Seattle, WA (US); and Dayle Lorand Sampson, Seattle, WA (US)
Assigned to IMMUNEXPRESS PTY LTD, Boonah (AU)
Appl. No. 15/765,162
Filed by ImmuneXpress Pty Ltd, Boonah (AU)
PCT Filed Sep. 30, 2016, PCT No. PCT/AU2016/050927
§ 371(c)(1), (2) Date Mar. 30, 2018,
PCT Pub. No. WO2017/054058, PCT Pub. Date Apr. 6, 2017.
Claims priority of application No. 2015903986 (AU), filed on Sep. 30, 2015.
Prior Publication US 2018/0305760 A1, Oct. 25, 2018
Int. Cl. C12Q 1/6883 (2018.01); G01N 33/68 (2006.01); C12Q 1/70 (2006.01)
CPC C12Q 1/6883 (2013.01) [C12Q 1/70 (2013.01); C12Q 1/701 (2013.01); G01N 33/6893 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/158 (2013.01); G01N 2800/26 (2013.01)] 13 Claims
 
1. A method for treating a virus-associated inflammatory response syndrome (VaSIRS) in a human subject, wherein the human subject has at least one clinical sign of SIRS, the method comprising:
(1) in a blood sample taken from the subject, measuring an expression level for a polynucleotide expression product of ISG15 and an expression level for a polynucleotide expression product of IL16;
(2) determining a derived biomarker value for the blood sample, wherein the derived biomarker value being a ratio of the expression level of the polynucleotide expression product of ISG15 to the expression level of the polynucleotide expression product of IL16;
(3) determining whether the derived biomarker value for the blood sample is greater than a reference derived biomarker value determined from expression levels for the polynucleotide expression product of ISG15 and the expression levels for the polynucleotide expression product of IL16 in samples from non-VaSIRS control subjects; and
(4) if the derived biomarker value for the blood sample is greater than the reference derived biomarker value, administering to the subject an effective amount of a VaSIRS therapeutic agent.